Francesco Prattichizzo

Francesco Prattichizzo
IRCCS Multimedica

Pharmaceutical doctor, PhD


How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
Additional affiliations
January 2015 - December 2018
IDIBAPS August Pi i Sunyer Biomedical Research Institute
  • PostDoc Position
January 2010 - April 2014
Università Politecnica delle Marche
  • PhD Student


Cited By


Project (1)
Project Dear Colleagues, Patients with both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) have a decreased life expectancy, mainly due to an increased incidence of cardiovascular (CV) diseases compared with people without these conditions. As demonstrated in specific trials, CV disease risk is attenuated, but not completely suppressed, by proper control of multiple risk factors (i.e., glucose, lipids, and blood pressure). Thus, diabetes might have an intrinsic, residual CV risk that is not fully addressed by available therapies. Emerging evidence suggests that a large range of molecular mechanisms and risk factors could explain such residual CV risk. In parallel, cardiovascular outcome trials (CVOTs) have disclosed a protective effect against CV and other complications for two recently introduced classes of glucose-lowering drugs (i.e., SGLT-2 inhibitors and GLP-1 receptor agonists). Of note, this effect is likely independent of their ability to lower glucose levels, further stressing the fact that additional research is needed to decipher the mechanisms driving the development of diabetes complications and the molecular underpinnings of the benefit provided by these novel drugs. Observational studies and pilot clinical trials suggest also that natural compounds might reduce the risk of developing T2DM complications (e.g., lipoic acid and diabetic neuropathy). Natural compounds can target specific pathways relevant for diabetes complications but can also eventually affect glucose homeostasis and lipid metabolism through a variety of mechanisms (i.e., inhibition/reduction of glucose, cholesterol and triglyceride transporters; stimulation of insulin secretion; reduction of serum cholesterol and triglycerides). Thus, they might represent an additional and alternative option to reduce the CV risk of patients with diabetes, especially those with intermediate/low risk. In this special issue, we seek for contributions exploring the effect of old and novel molecular mechanisms to the development of diabetes complications, particularly the CV ones. Clinical studies assessing the relevance of non-canonical risk factors to the development of CV diseases in patients with diabetes are also welcomed, as long as they explore also an associated molecular mechanism. Finally, studies exploring the underpinnings of the effect of glucose-lowering drugs (old or novel) are also of great interest. Manuscripts dealing with T2DM are a priority while papers on T1DM are also encouraged, as long as they deal with the development of CV complications. Original research papers, short-communications, and reviews, both narrative and systematic, are all eligible pieces for this special issue. Meta-analyses focusing only on clinical outcomes are not within the scope of this special issue. Dr. Francesco Prattichizzo Dr. Giulia Matacchione Guest Editors